AbbVie to Acquire Apogee Therapeutics
AbbVie plans to acquire Apogee Therapeutics, expanding its immunology portfolio with a diverse pipeline of innovative therapies for dermatologic, respiratory, inflammatory, and immune-mediated diseases.
Asthma Treatment | 23/06/2026 | By News Bureau
Sanofi's Lunsekimig Shows Promising Phase II Results in Asthma and Nasal Polyps Studies
The novel dual-targeting Nanobody met primary and key secondary endpoints in asthma and chronic rhinosinusitis trials, demonstrating improved outcomes and a favourable safety profile.
Asthma Treatment | 08/04/2026 | By News Bureau | 109
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy